Daitch J A, Angermeier K W, Lakin M M, Ingleright B J, Montague D K
Department of Urology, The Cleveland Clinic Foundation, Ohio, USA.
J Urol. 1997 Oct;158(4):1400-2.
Recently, we have noted an increasing incidence of revisions being performed in patients implanted with the length and girth expanding AMS 700 Ultrex* inflatable penile prosthesis. This observation prompted us to compare the long-term mechanical reliability of the AMS Ultrex inflatable penile prosthesis versus the girth-expanding AMS 700 CX* or CXM* inflatable penile prosthesis in men with organic erectile dysfunction.
Using chart review, mailed questionnaires and telephone interviews, we obtained accurate followup on 111 of 142 (78.2%) patients with CX/CXM implanted between June 1986 and September 1995, and on 152 of 179 (84.9%) patients implanted with Ultrex between October 1989 and September 1995. The CX/CXM and Ultrex groups were compared with regard to 3 end points: 1) mechanical failure caused by any malfunctioning component, 2) device failure caused by any cylinder complication and 3) cylinder aneurysms/leaks.
Followup ranged from 1.0 to 112.0 months for the CX/CXM group (mean 47.2 months), and 0.7 to 71.5 months for the Ultrex group (mean 34.4 months). CX/CXM versus Ultrex group comparison demonstrated 10 CX/CXM mechanical failures (9.0%) versus 26 Ultrex failures (17.1%), p = 0.001; 5 CX/CXM cylinder complications (4.5%) versus 13 Ultrex cylinder complications (8.6%), p = 0.0292; and 3 CX/CXM cylinder aneurysms/leaks (2.7%) versus 9 in the Ultrex group (5.9%), p = 0.0162. Kaplan-Meier estimates demonstrated significantly decreased mechanical survival in all 3 categories for Ultrex inflatable penile prosthesis versus CX/CXM inflatable penile prosthesis.
Although Ultrex cylinders provide length and girth expansion, Ultrex cylinders exhibit an increased mechanical failure rate at shorter followup compared with CX/CXM cylinders. This increased propensity for Ultrex cylinder problems should be closely monitored.
最近,我们注意到接受长度和周长可扩展的美国医药系统公司(AMS)700 Ultrex* 可膨胀阴茎假体植入的患者中,翻修手术的发生率在不断上升。这一观察结果促使我们比较AMS Ultrex可膨胀阴茎假体与周长可扩展的AMS 700 CX* 或CXM* 可膨胀阴茎假体在器质性勃起功能障碍男性中的长期机械可靠性。
通过查阅病历、邮寄问卷和电话访谈,我们对1986年6月至1995年9月间植入CX/CXM的142例患者中的111例(78.2%),以及1989年10月至1995年9月间植入Ultrex的179例患者中的152例(84.9%)进行了准确的随访。比较CX/CXM组和Ultrex组的3个终点:1)由任何故障部件导致的机械故障;2)由任何圆柱体并发症导致的装置故障;3)圆柱体动脉瘤/渗漏。
CX/CXM组的随访时间为1.0至112.0个月(平均47.2个月),Ultrex组为0.7至71.5个月(平均34.4个月)。CX/CXM组与Ultrex组比较显示,CX/CXM组有10例机械故障(9.0%),而Ultrex组有26例故障(17.1%),p = 0.001;CX/CXM组有5例圆柱体并发症(4.5%),Ultrex组有13例圆柱体并发症(8.6%),p = 0.0292;CX/CXM组有3例圆柱体动脉瘤/渗漏(2.7%),Ultrex组有9例(5.9%),p = 0.0162。Kaplan-Meier估计显示,与CX/CXM可膨胀阴茎假体相比,Ultrex可膨胀阴茎假体在所有3类中的机械存活率均显著降低。
尽管Ultrex圆柱体可实现长度和周长扩展,但与CX/CXM圆柱体相比,在较短随访期内,Ultrex圆柱体的机械故障率有所增加。应密切监测Ultrex圆柱体问题的这种增加趋势。